Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival
World Journal of Gastroenterology · 2024
DOI: 10.3748/wjg.v30.i7.714 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastroenterology, 2024. Verfasst von Pui-Yin Leung und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, United States. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Adenocarcinoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
BACKGROUND Pancreatic cancer is a leading cause of cancer-related deaths. Increased activity of the epidermal growth factor receptor (EGFR) is often observed in pancreatic cancer, and the small molecule EGFR inhibitor erlotinib has been approved for pancreatic cancer therapy by the food and drug administration. Nevertheless, erlotinib alone is ineffective and should be combined with other drugs to improve therapeutic outcomes. We previously showed that certain receptor tyrosine kinase inhibitors can increase mitochondrial membrane potential (Δψm), facilitate tumor cell uptake of Δψm-sensitive agents, disrupt mitochondrial homeostasis, and subsequently trigger tumor cell death. Erlotinib has not been tested for this effect. AIM To determine whether erlotinib can elevate Δψm and increase tumor cell uptake of Δψm-sensitive agents, subsequently triggering tumor cell death. METHODS Δψm-sensitive fluorescent dye was used to determine how erlotinib affects Δψm in pancreatic adenocarcinoma (PDAC) cell lines. The viability of conventional and patient-derived primary PDAC cell lines in 2D- and 3D cultures was measured after treating cells sequentially with erlotinib and mitochondria-targeted ubiquinone (MitoQ), a Δψm-sensitive MitoQ. The synergy between erlotinib and MitoQ was then analyzed using SynergyFinder 2.0. The preclinical efficacy of the two-drug combination was determined using immune-compromised nude mice bearing PDAC cell line xenografts. RESULTS Erlotinib elevated Δψm in PDAC cells, facilitating tumor cell uptake and mitochondrial enrichment of Δψm-sensitive agents. MitoQ triggered caspase-dependent apoptosis in PDAC cells in culture if used at high doses, while erlotinib pretreatment potentiated low doses of MitoQ. SynergyFinder suggested that these drugs synergistically induced tumor cell lethality. Consistent with in vitro data, erlotinib and MitoQ combination suppressed human PDAC cell line xenografts in mice more effectively than single treatments of each agent. CONCLUSION Our findings suggest that a combination of erlotinib and MitoQ has the potential to suppress pancreatic tumor cell viability effectively.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, United States.
- Department of Surgery, Medical College of Wisconsin, Milwaukee, WI 53226, United States.
- Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, United States. jipark@mcw.edu.
Förderung
- NCI NIH HHS
Zitieren
APA
Leung, P. Y., Chen, W., Sari, A. N., Sitaram, P., Wu, P. K., Tsai, S., & Park, J. I. (2024). Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.v30.i7.714
Vancouver
Leung PY, Chen W, Sari AN, Sitaram P, Wu PK, Tsai S, et al. Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival. World Journal of Gastroenterology. 2024. doi:10.3748/wjg.v30.i7.714
BibTeX
@article{Leung2024,
author = {Leung, Pui-Yin and Chen, Wenjing and Sari, Anissa N and Sitaram, Poojitha and Wu, Pui-Kei and Tsai, Susan and Park, Jong-In},
title = {Erlotinib combination with a mitochondria-targeted ubiquinone effectively suppresses pancreatic cancer cell survival},
journal = {World Journal of Gastroenterology},
year = {2024},
doi = {10.3748/wjg.v30.i7.714}
}
EUVIMED